February 2019
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
Immunotherapy studies for triple-negative breast cancer
Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. At Providence Cancer Institute, two Phase 3 immunotherapy studies are open now for women with metastatic and non-metastatic TNBC :


All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.